Rivarutamide

Developed for: salivary gland carcinoma
Investigated by: Peking Union Medical College · Peking University Hospital of Stomatology

today NCT06145308 · Ph 2

20242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT06145308	Aug 2023 → Jul 2028 expected	salivary gland carcinoma	Peking Union Medical College	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Rivarutamide	“Rivarutamide 240mg po qd” NCT06145308 ↗
Route	Oral	“Rivarutamide 240mg po qd” NCT06145308 ↗